164 related articles for article (PubMed ID: 28029541)
1. Funding gap for immunization across 94 low- and middle-income countries.
Ozawa S; Grewal S; Portnoy A; Sinha A; Arilotta R; Stack ML; Brenzel L
Vaccine; 2016 Dec; 34(50):6408-6416. PubMed ID: 28029541
[TBL] [Abstract][Full Text] [Related]
2. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
3. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
[TBL] [Abstract][Full Text] [Related]
4. Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study.
Ikilezi G; Micah AE; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL
Lancet; 2021 Nov; 398(10314):1875-1893. PubMed ID: 34742369
[TBL] [Abstract][Full Text] [Related]
5. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
6. Financing And Funding Gap For 16 Vaccines Across 94 Low- And Middle-Income Countries, 2011-30.
Sriudomporn S; Sim SY; Mak J; Brenzel L; Patenaude BN
Health Aff (Millwood); 2023 Jan; 42(1):94-104. PubMed ID: 36623227
[TBL] [Abstract][Full Text] [Related]
7. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
[TBL] [Abstract][Full Text] [Related]
8. Tracking financial flows for immunization in Honduras.
Valdés W; Janusz CB; Molina Aguilera IB; Mendoza L; Díaz IY; Resch S
Vaccine; 2015 May; 33 Suppl 1():A85-92. PubMed ID: 25919182
[TBL] [Abstract][Full Text] [Related]
9. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
11. Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021-2030.
Sriudomporn S; Watts E; Yoon Sim S; Hutubessy R; Patenaude B
Vaccine X; 2023 Apr; 13():100256. PubMed ID: 36686400
[TBL] [Abstract][Full Text] [Related]
12. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries.
Stenberg K; Hanssen O; Edejer TT; Bertram M; Brindley C; Meshreky A; Rosen JE; Stover J; Verboom P; Sanders R; Soucat A
Lancet Glob Health; 2017 Sep; 5(9):e875-e887. PubMed ID: 28728918
[TBL] [Abstract][Full Text] [Related]
13. Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization.
Thomas Mori A; Christopher Bulula N; Magodi R; Mwengee W
Vaccine; 2022 May; 40(24):3278-3285. PubMed ID: 35527062
[TBL] [Abstract][Full Text] [Related]
14. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
[TBL] [Abstract][Full Text] [Related]
15. Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990-2016).
Ikilezi G; Zlavog B; Augusto OJ; Sherr K; Lim SS; Dieleman JL
Vaccine; 2018 Nov; 36(49):7487-7495. PubMed ID: 30366804
[TBL] [Abstract][Full Text] [Related]
16. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
[TBL] [Abstract][Full Text] [Related]
17. Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.
Gandhi G; Lydon P
BMC Public Health; 2014 Jan; 14():67. PubMed ID: 24450832
[TBL] [Abstract][Full Text] [Related]
18. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
[TBL] [Abstract][Full Text] [Related]
19. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
[TBL] [Abstract][Full Text] [Related]
20. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
